APLS Apellis Pharmaceuticals

Apellis Initiates Registrational Programs of Pegcetacoplan in Patients with C3G / IC-MPGN and ALS, Rare Diseases with High Unmet Need

Apellis Initiates Registrational Programs of Pegcetacoplan in Patients with C3G / IC-MPGN and ALS, Rare Diseases with High Unmet Need
EN
05/10/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Apellis Pharmaceuticals

Wedbush Research
  • Wedbush Research
 PRESS RELEASE

Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Fina...

Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results Full-year 2025 net product revenues of $689 million SYFOVRE® (pegcetacoplan injection) full year 2025 net product revenue of $587 millionEMPAVELI® (pegcetacoplan) full year 2025 net product revenue of $102 million Regulatory submission for SYFOVRE prefilled syringe planned for the first half of 2026EMPAVELI franchise has strong momentum with successful launch in C3G and primary IC-MPGN, and pivotal trials underway in FSGS and DGFCash and cash equivalents of $466 million as of December 31, 2025; projected rev...

 PRESS RELEASE

Apellis Pharmaceuticals to Present at the TD Cowen 46th Annual Health ...

Apellis Pharmaceuticals to Present at the TD Cowen 46th Annual Health Care Conference WALTHAM, Mass., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the company will participate in a webcast fireside chat at the TD Cowen 46th Annual Health Care Conference on Monday, March 2, 2026, at 9:50 a.m. ET. The live conference webcast will be posted on the “Events and Presentations” page of the “Investors and Media” section of the company’s . A replay of the webcast will be available for approximately 30 days following the event. About ApellisA...

Wedbush Research
  • Wedbush Research

ResearchPool Subscriptions

Get the most out of your insights

Get in touch